Sign Of The Times? Micromet’s Stock Price Sluggish Despite Reasons For Optimism
Biotech well-funded thanks to recent deals and sees blockbuster potential in lymphoma with blinatumomab.
More from Archive
More from Pink Sheet
• By
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
• By
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
• By
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.